Oramed Pharmaceuticals Management
Management Kriterienprüfungen 3/4
Oramed Pharmaceuticals' CEO is Nadav Kidron, appointed in Mar 2006, has a tenure of 18.67 years. total yearly compensation is $1.66M, comprised of 27.9% salary and 72.1% bonuses, including company stock and options. directly owns 2.45% of the company’s shares, worth $2.32M. The average tenure of the management team and the board of directors is 11.9 years and 8.2 years respectively.
Wichtige Informationen
Nadav Kidron
Geschäftsführender
US$1.7m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 27.9% |
| Amtszeit als Geschäftsführer | 18.7yrs |
| Eigentum des Geschäftsführers | 2.4% |
| Durchschnittliche Amtszeit des Managements | 11.9yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 8.2yrs |
Jüngste Management Updates
Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$21m |
| Mar 31 2024 | n/a | n/a | US$10m |
| Dec 31 2023 | US$2m | US$463k | US$6m |
| Sep 30 2023 | n/a | n/a | -US$16m |
| Jun 30 2023 | n/a | n/a | -US$20m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$7m | US$491k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$46m |
| Jun 30 2022 | n/a | n/a | -US$46m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | n/a | n/a | -US$35m |
| Nov 30 2021 | n/a | n/a | -US$25m |
| Aug 31 2021 | US$4m | US$466k | -US$22m |
| May 31 2021 | n/a | n/a | -US$18m |
| Feb 28 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | n/a | n/a | -US$22m |
| Nov 30 2020 | n/a | n/a | -US$15m |
| Aug 31 2020 | US$2m | US$439k | -US$12m |
| May 31 2020 | n/a | n/a | -US$11m |
| Feb 29 2020 | n/a | n/a | -US$13m |
| Nov 30 2019 | n/a | n/a | -US$13m |
| Aug 31 2019 | US$2m | US$419k | -US$14m |
| May 31 2019 | n/a | n/a | -US$15m |
| Feb 28 2019 | n/a | n/a | -US$15m |
| Nov 30 2018 | n/a | n/a | -US$14m |
| Aug 31 2018 | US$2m | US$436k | -US$13m |
Vergütung im Vergleich zum Markt: Nadav's total compensation ($USD1.66M) is above average for companies of similar size in the US market ($USD655.65K).
Entschädigung vs. Einkommen: Nadav's compensation has been consistent with company performance over the past year.
Geschäftsführer
Nadav Kidron (50 yo)
18.7yrs
Amtszeit
US$1,659,222
Vergütung
Mr. Nadav Kidron, Esq. has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Technologies Inc) since March 08, 2006. Mr. Kidron served as an i...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 18.7yrs | US$1.66m | 2.45% $ 2.3m | |
| Chief Scientific Officer & Director | 18.7yrs | US$1.11m | 0.21% $ 199.9k | |
| CFO, Treasurer & Secretary | less than a year | US$1.05m | keine Daten | |
| Chief Operating & Business Officer | 5.2yrs | US$1.28m | 0.42% $ 401.0k |
11.9yrs
Durchschnittliche Betriebszugehörigkeit
52yo
Durchschnittliches Alter
Erfahrenes Management: ORMP's management team is seasoned and experienced (11.9 years average tenure).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 18.7yrs | US$1.66m | 2.45% $ 2.3m | |
| Chief Scientific Officer & Director | 18.7yrs | US$1.11m | 0.21% $ 199.9k | |
| Member of Scientific Advisory Board | 4.8yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 17.8yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 8yrs | US$20.00k | keine Daten | |
| Member of Scientific Advisory Board | 16.3yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 4.9yrs | keine Daten | keine Daten | |
| Independent Director | 17.1yrs | US$112.28k | 0.080% $ 75.5k | |
| Member of the Scientific Advisory Board | 8.3yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 2.4yrs | keine Daten | keine Daten | |
| Independent Director | 4.9yrs | US$127.28k | 0.075% $ 71.1k | |
| Member of Scientific Advisory Board | 4.8yrs | keine Daten | keine Daten |
8.2yrs
Durchschnittliche Betriebszugehörigkeit
70yo
Durchschnittliches Alter
Erfahrener Vorstand: ORMP's board of directors are considered experienced (8.2 years average tenure).